In relation to nicotine dependence, cannabinoid receptor 1 (CB1R) antagonists, such as rimonabant, decrease nicotine conditioned place preference and self‐administration in pre‐clinical models of addiction 16, 17. The gene discussed is CNR1; the disease is nicotine dependence.